#United States #New York City #CytoSorbents #Blood Purification #CytoSorb

CytoSorbents' Participation at the Annual Investment Conference

CytoSorbents Corporation, a prominent player in the medical technology field focused on the treatment of critical conditions in intensive care, is gearing up for its significant appearance at the H.C. Wainwright's 28th Annual Global Investment Conference to be held from September 14 to September 16, 2026, in New York City. This event represents a vital platform for companies of note to showcase their innovations and strategies to investors and industry analysts alike.

The Experts Behind the Discussion

Leading the representation for CytoSorbents will be Dr. Phillip Chan, the Chief Executive Officer, and Peter Mariani, the Chief Financial Officer. Their participation is expected to highlight the company’s unique approach to blood purification, as they engage in a fireside chat with Sean Lee, Vice President of Equity Research at H.C. Wainwright. This intimate conversation promises to shed light on the company’s trajectory, its market positions, and future objectives, making it a noteworthy session for potential investors.

Fireside Chat Details

• - Date: Monday, September 14, 2026
• - Time: 11:30 AM EDT
• - Location: Lotte New York Palace Hotel, New York, NY
• - Webcast Link: Fireside Chat Webcast

Following the event, the webcast will be accessible for up to 90 days, enabling a broader audience to engage with the discussions and insights shared during the conference.

CytoSorbents' Groundbreaking Technology

CytoSorbents harnesses innovative blood purification technology, which plays a crucial role in treating life-threatening conditions within ICU settings and during cardiac surgeries. At the heart of their offering is the CytoSorb® device, which utilizes biocompatible, porous polymer beads designed to effectively capture and remove harmful substances from blood and bodily fluids. This technology is particularly vital for patients undergoing procedures where blood thinners might increase the risk of complications, including excessive bleeding during surgery.

The applications of CytoSorbents' technology extend across various critical illnesses including sepsis, severe trauma, and liver failure. The efficacy of CytoSorb® has been validated through its utilization in over 70 countries, reinforcing its significance in the medical community. With more than 300,000 devices deployed, the company continues to demonstrate the life-saving impact of their products.

Furthermore, the technology has been granted Emergency Use Authorization by the FDA for use in critically ill COVID-19 patients experiencing respiratory failure, showcasing its flexibility and relevance in urgent medical scenarios, even amidst global public health crises.

Future Endeavors and Innovations

Beyond their flagship product, CytoSorbents is advancing its portfolio with the development of the DrugSorb®-ATR system, which aims to mitigate perioperative bleeding in high-risk surgeries. This investigational device is in line with their innovative blood purification framework and has been designated as a Breakthrough Device by the FDA. With ongoing efforts to secure regulatory approvals in both the United States and Canada, the company is poised for significant growth.

CytoSorbents is also actively engaged in the continuous development of additional products that leverage their proprietary technology, supported by an extensive array of patents and a commitment to R&D excellence. Innovations like ECOS-300CY®, HemoDefend-RBC™, and several others underline their focus on expanding treatment options available to hospitals and healthcare providers.

Connecting with the Community

The H.C. Wainwright 28th Annual Global Investment Conference serves as an opportunity not only for CytoSorbents to connect with potential investors but also to engage with patients, clinicians, and stakeholders who may benefit from their life-saving technologies. CytoSorbents stands as a testament to the power of innovation in healthcare, ensuring that every patient receives the best possible care through advanced medical solutions.

For additional details about CytoSorbents and their products, please visit www.cytosorbents.com.

As the countdown to the conference begins, all eyes will be on CytoSorbents as they continue to pave the way for pioneering advancements in blood purification treatments, underscoring the integral role of investor support for health innovations.